Are peptides legal now? The 2026 timeline, untangled

TL;DR

• Three separate 2026 events got compressed into one headline - an April delisting, a July advisory vote, and a listing that still hasn't happened.
• April 2026 removed twelve substances from Category 2, which leaves them in no category rather than Category 1 - it authorised no compounding and restored no channel.
• On 23–24 July 2026 the PCAC recommended six of seven peptides for the 503A Bulks List - BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon - and declined emideltide (DSIP), over the written objection of the FDA's own career scientists. The vote was non-binding.
• As of 19 October 2026 nothing has been added to the 503A Bulks List - no proposed rule, the six not listed, the HHS Secretary's formal approval not given, and no interim enforcement policy issued. A draft interim policy went to White House (OMB) review on 14 October 2026; its text is not public, and enforcement discretion would not be a listing or an approval.
• Listing requires full notice-and-comment rulemaking plus formal approval by the Secretary of Health and Human Services - both outstanding, no completion date set, and the FDA is not bound to proceed at all. No lawful route to compounding these peptides exists via this path today.
• Nothing was banned either. 2026 moved these peptides further through review than at any point since 2023; whether, when and in what form supervised access follows is still an open question, not a closed one.

Educational content, not medical advice. No doses or protocols appear anywhere; any use is physician-directed with verified product. The compounds named are investigational and not FDA-approved. "Reclassified," "recommended," and "approved" are three different legal statuses.

Updated October 2026: re-dated to 19 October 2026. Adds the 14 October 2026 submission of the FDA's draft "Interim Access Policy for Compounding Using Certain Peptides" to OMB/OIRA review: not issued, text not public, and if it takes the expected enforcement-discretion form it would list nothing, approve nothing, and not cover research-use-only products, supplements or 503B. Language that could read as "access is on its way" has been tightened; Event C still has not happened.

Updated 28 September 2026: factual correction - this page previously equated "Category 1" with the 503A Bulks List. They are different things: Category 1 is the FDA's interim category of nominated substances under evaluation, not the list itself, and none of these peptides is in it. Also replaced the "8 to 24 months / late 2027" timeline estimates with status statements; no completion date is predicted.

Updated September 2026: re-dated to 15 September 2026 and the status line sharpened in this page's own three-event framing, recommended is not listed and listed is not legal: six peptides were recommended in July, emideltide (DSIP) was not, and as of 15 September 2026 nothing has been added to the 503A Bulks List, with notice-and-comment rulemaking and formal approval by the Secretary of Health and Human Services both still outstanding. The second-meeting marker is corrected from "scheduled for review by February 2027" to expected before the end of February 2027, with no date published by the FDA.

Updated 13 September 2026: Event A has been materially corrected. This page previously described the April 2026 action as a move from Category 2 to Category 1 that "restored a supervised compounding channel." That is not what happened, and it is the single most commonly repeated error about this sequence. The FDA removed twelve substances from Category 2; removal does not place a substance on the 503A Bulks List and does not confer Category 1 status. The affected peptides now sit in no category at all. No lawful compounding channel was restored in April, and none exists today. The rest of the timeline is unchanged and still accurate.

Updated September 2026: confirms Event C still has not happened: as of 13 September 2026 no proposed rule has been published, the six recommended peptides are not on the final 503A Bulks List, and no interim enforcement policy has been announced.

---

Almost every peptide headline in 2026 has collapsed a slow, three-step regulatory process into a single misleading word - "legal." The result is a lot of people who believe BPC-157 was approved, or that they can now buy it off a shelf, or conversely that it was banned. None of those is right, and the confusion isn't harmless: the gap between the July vote and real availability is exactly the window in which grey-market sellers push "research-only" product on the strength of a headline. This page lays the three events on a timeline and states plainly what each one did - and did not - do.

The one-line version

Delisted ≠ Recommended ≠ Listed. Three different things happened (or, in the third case, didn't), on three different dates, with three different legal meanings. Keep them separate and the whole picture snaps into focus. The crucial point, and the one every version of this story gets wrong: none of the three has yet made compounding lawful.

Event A - the April 2026 Category 2 removal

The first event is the one most people have forgotten, and it is also the one most often described wrongly - including, until this update, on this page. Following a policy push associated with HHS leadership announced in late February 2026, the FDA removed a batch of substances from compounding Category 2. The action was published in the Federal Register in mid-April and took effect later that month. Twelve substances came off: the seven that went on to the July advisory meeting - BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax and Epitalon - plus GHK-Cu in injectable routes, Melanotan II, LL-37, dihexa acetate and PEG-MGF, which go to a second committee meeting expected before the end of February 2027 - the FDA has published no date for it.

Here is what that did and did not do. Category 2 is the list of substances the FDA has flagged as presenting significant safety concerns; being on it is a stated reason a substance should not be compounded. Coming off it removes that stated reason. It does not move the substance to Category 1, and it does not put it on the 503A Bulk Drug Substances List - which are two different things. Category 1 is the FDA's interim category for nominated substances it is still evaluating; the 503A Bulks List is the list created by final rule. Under the statute, a bulk substance with no USP/NF monograph that is not a component of an approved drug can only be lawfully compounded once it is on the Bulks List. A substance removed from Category 2 and not placed anywhere else is in no category at all: not barred on safety grounds, not permitted either.

So the April action did not restore a supervised compounding channel, because there was no channel to restore and none was created. It cleared an obstacle to the review that happened in July. Anyone told in 2026 that a doctor and a pharmacy can now lawfully compound BPC-157 from bulk has been told something that is not true. The deeper mechanics are in the 2026 FDA peptide reclassification, explained and what "503A compounding" actually means.

Event B - the July 2026 advisory vote

The second event is the one that made the headlines - and the one most over-read. On 23–24 July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides and recommended six of them - BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon - for the 503A Bulk Drug Substances List, declining only emideltide (also called DSIP).

Two features of that vote matter more than the tally. First, it was advisory and non-binding: the committee makes a recommendation, and the FDA is free to accept or decline it. Second, the committee recommended these compounds over the written objection of the FDA's own career scientists, who had reviewed the same evidence and advised against listing all seven. So the vote is a genuine signal about where the debate is heading - and a poor basis for concluding anything is now "legal." A recommendation is a step, not a finish line. The full recap is in after the FDA vote: what changed.

Event C - the approval that hasn't happened

The third "event" is the one everyone is behaving as if it already occurred. It hasn't - and nearly three months on from the vote, it still hasn't. As of 19 October 2026 the FDA has not published a proposed rule. Nothing has been added to the 503A Bulks List - the six recommended peptides are not on it - and no interim enforcement policy has been issued, so there is no transitional arrangement permitting compounding in the meantime. For any of these peptides to actually be added to the 503A Bulks List, the FDA has to run notice-and-comment rulemaking: publish a proposed rule, open a public comment period (typically 60–90 days), weigh the comments, and issue a final rule - and the Secretary of Health and Human Services has to formally approve the addition. None of those steps has happened, no completion date has been set, and at any point the FDA can decline to follow the July recommendation. No lawful route to a licensed pharmacy compounding, say, BPC-157 exists via this path today. Until a final rule exists, nothing has been approved and nothing new is lawfully purchasable. This is the step the headlines skip entirely.

The October development is not Event C. On 14 October 2026 HHS/FDA sent a draft "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Information and Regulatory Affairs at the White House Office of Management and Budget for review. It has not been issued and its text is not public; reports that it would include BPC-157 ran ahead of any published document. Law-firm analysis expects enforcement discretion, possibly by placing certain peptides in Category 1 - the FDA signalling it would not plan to act against 503A pharmacies compounding them for individual patients, under conditions. That would not add anything to the 503A Bulks List, approve any product or change the statute; it could be narrowed or withdrawn without notice-and-comment; and it would not cover research-use-only products, dietary supplements or 503B outsourcing facilities, or bind state boards of pharmacy and medicine. FDA funding runs under a temporary spending measure through 11 December 2026, which adds timeline risk. A draft under review is a fourth thing to keep separate, not a shortcut through the third.

So what does this mean for me?

The honest answer is a timeline, not a source. If you're waiting for legitimate, supervised access to a compound like BPC-157, the milestone to watch is a final rule, not a committee vote - and as of today no proposed rule has even been published. In the meantime, the compounds that were reviewed are exactly what they were in June: investigational, largely lacking controlled human trials, and only as safe as their sourcing and supervision.

Why the gap matters

The interval between the July vote and real availability is the dangerous part. Transitional moments are when the grey market gets loudest - "buy it before it's regulated," "get it while it's still research-only" - and a committee recommendation gives that pitch a fresh coat of paint and none of the substance. Enforcement through 2026 escalated from warning letters to criminal charges against sellers, and vendors have vanished overnight, which is its own supply risk for anyone mid-course. A vote does not change what is in a vial, and it does not turn a legal disclaimer into a safety guarantee. The durable position is unchanged, and it is not a checklist you run yourself: physician supervision, a clinician who takes responsibility for what you are supplied, and honest expectations - see which peptides are legal in 2026.

The four misreadings to retire

• "Peptides are approved now." No - no FDA approval occurred. A reclassification and an advisory recommendation are not approvals. (And "approved" is not one status either - what accelerated approval actually means separates the pathways and designations that marketing routinely blurs together.)
• "It's legal to buy them now." No - no new purchase pathway opened. Lawful compounding depends on rulemaking that hasn't finished.
• "They were banned." Also no - the April action removed these substances from a restriction list, and the July vote was favourable to six of seven. Neither event created a lawful channel, but neither closed one either.
• "It's basically over, just paperwork now." No - the FDA isn't bound by the vote, rulemaking can change or stall, and none of it has started.

What's next

There's a forward marker worth knowing: a second PCAC meeting is expected before the end of February 2027, covering five more peptides - reported to include LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF. The FDA has published no date for that meeting, and no stated reason for splitting the peptide review across two sittings; treat any specific date circulating now as provisional. Together the two sittings address twelve of the nineteen peptides placed in Category 2 in 2023, which makes this a phased, compound-by-compound review rather than a blanket reversal - each substance is judged individually against the 503A criteria. That cycle will generate its own round of "is it legal now?" headlines, and the same three-status discipline will apply to it. (For where GHK-Cu specifically sits ahead of that meeting, see injectable GHK-Cu's legal limbo.)

Frequently asked questions

Are peptides legal to buy right now? No new purchase pathway opened in 2026, and no lawful compounding pathway opened either. The April action removed certain peptides from Category 2, which left them in no category rather than placing them on the 503A Bulks List; the July advisory vote was a non-binding recommendation. Neither authorises retail or "research use only" sales, neither authorises a pharmacy to compound from bulk, and actual Bulks-List placement awaits rulemaking that has not begun.

Is BPC-157 approved now? No. BPC-157 was recommended by an advisory committee in July 2026 - a non-binding step - and it was one of the twelve substances removed from Category 2 in April, but it is not FDA-approved and not on the 503A list. Adding it requires notice-and-comment rulemaking the FDA is not obligated to complete.

When can I actually get these from a licensed pharmacy? There is no date. Lawful compounding of these substances on a permanent basis happens only if the FDA completes rulemaking to place a compound on the 503A list, and as of 19 October 2026 no proposed rule has been published. A draft interim enforcement policy has been at White House review since 14 October 2026, but it has not been issued, its scope is unknown, and it would not reach research-use-only sellers. The honest answer is a status, not a source - and anyone offering a source today is skipping the two steps that haven't happened.

Were peptides banned in 2026? No. 2026 brought a Category 2 removal in April, a favourable (if non-binding) advisory vote in July, and a draft interim policy sent to White House review in October. None of those has delivered lawful access - the open question is whether legitimate access arrives, in what form and when, not whether a ban is in force.

Related reading

• The 2026 FDA peptide reclassification, explained · After the FDA vote: what changed · What is 503A compounding? · Which peptides are legal in 2026 · What accelerated approval actually means
• Part of The Complete Guide to Peptides

---

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore BPC-157.

---

Educational content, not medical advice. The compounds named are investigational and not FDA-approved. Removal from Category 2 does not permit compounding; for these substances only placement on the 503A Bulks List by final rule would, and none of them has been placed there. A PCAC recommendation is non-binding and does not place anything on the 503A Bulks List. No purchase pathway that does not yet legally exist is implied here. Claims for the Malaysian market are subject to MAB requirements. Dates and steps reflect the position as of 19 October 2026 and will be updated as the FDA acts.

References

• Category 2 removal for twelve substances (not a move to Category 1 - this page previously described it that way and the description was wrong): HHS/FDA policy announced late February 2026; FDA action April 2026; Federal Register 16 April 2026; effective late April 2026 (see Pharmacy Times analysis; Orrick regulatory brief). Sources differ on whether the effective date was 22 or 23 April; the discrepancy is unresolved and should be settled against the Federal Register notice before publication. · FDA Pharmacy Compounding Advisory Committee, 23–24 July 2026: recommended 6 of 7 peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) for the 503A Bulk Drug Substances List; DSIP not recommended; committee recommended over FDA staff's written objection (National Law Review; Mintz; McDermott Will & Emery; AJMC; The Hill). · Recommendations non-binding; Bulks-List placement requires notice-and-comment rulemaking (proposed rule → public comment → final rule) plus formal approval by the Secretary of Health and Human Services, both outstanding; FDA not bound to follow PCAC. · FDA interim policy (final guidance January 2025): Category 1 = nominated substances under evaluation that FDA does not currently intend to act against; distinct from the 503A Bulks List established by rule (fda.gov, "Bulk Drug Substances Used in Compounding Under Section 503A"). As of 19 October 2026 nothing has been added to the 503A Bulks List. · Draft "Interim Access Policy for Compounding Using Certain Peptides" submitted to OIRA/OMB for review on 14 October 2026; not issued, text not public; expected enforcement-discretion mechanism, possibly via Category 1; would not cover research-use-only products, dietary supplements or 503B, and would not bind state boards - Holland & Knight, "Peptides at a Crossroads" (October 2026) (https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know); Buchanan Ingersoll & Rooney, 16 October 2026 (https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know); Becker's Hospital Review, 15 October 2026 (https://www.beckershospitalreview.com/glp-1s/hhs-sends-peptide-compounding-plan-to-white-house-5-things-to-know/). · Second PCAC meeting expected before end of February 2027, reported to cover LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF; no date published by the FDA and no stated reason published for splitting the review across two meetings - do not cite either. The two meetings together address twelve of the nineteen peptides placed in Category 2 in 2023. · All dates to be re-verified against the Federal Register and FDA notices before publication.